- Previous Close
14.50 - Open
14.60 - Bid 14.40 x --
- Ask 14.80 x --
- Day's Range
14.60 - 14.60 - 52 Week Range
7.65 - 21.20 - Volume
140 - Avg. Volume
1,149 - Market Cap (intraday)
231.6M - Beta (5Y Monthly) 1.13
- PE Ratio (TTM)
-- - EPS (TTM)
-0.94 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
4basebio PLC engages in the research, development, manufacturing, and commercialization of synthetic DNA and RNA products, and targeted non-viral vector solutions in the United States, Europe, and internationally. The company offers AVV and Lentivirus manufacturing services for use in gene therapies and vaccines. It also offers access to its targeted non-viral delivery platform, Hermes. The company was formerly known as 4basebio UK Societas and changed its name to 4basebio PLC in July 2021. 4basebio PLC was founded in 2008 and is based in Cambridge, the United Kingdom.
www.4basebio.comRecent News: 88Q.DE
View MorePerformance Overview: 88Q.DE
Trailing total returns as of 1/9/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 88Q.DE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 88Q.DE
View MoreValuation Measures
Market Cap
233.37M
Enterprise Value
242.28M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
250.67
Price/Book (mrq)
--
Enterprise Value/Revenue
337.01
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-54.30%
Return on Equity (ttm)
--
Revenue (ttm)
596k
Net Income Avi to Common (ttm)
-9.84M
Diluted EPS (ttm)
-0.94
Balance Sheet and Cash Flow
Total Cash (mrq)
2.72M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-7.06M